-+ 0.00%
-+ 0.00%
-+ 0.00%

MINK THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RANDOMIZED PHASE 2 TRIAL OF AGENT-797 IN ACUTE LUNG INJURY AND CRITICAL ILLNESS

Reuters·05/28/2026 13:04:49

Please log in to view news